Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17582307 | 0.97 | — | — | |
| SCHEMBL25745100 | 0.97 | — | — | |
| SCHEMBL541485 | 0.88 | GRM1 (0.34) | GRM1 | |
| SCHEMBL23663192 | 0.83 | GRM1 (0.34) | GRM1 | |
| SCHEMBL16699200 | 0.78 | GRM1 (0.33) | GRM1 | |
| SCHEMBL25615317 | 0.78 | GRM1 (0.33) | GRM1 | |
| SCHEMBL1648486 | 0.77 | GRM1 (0.50) | GRM1 | |
| SCHEMBL9142496 | 0.77 | GRM1 (0.50) | GRM1 | |
| SCHEMBL1073494 | 0.76 | PKM (0.36) | — | |
| Hydrochloric Acid SCHEMBL5480359 | 0.74 | GRM1 (0.48) | GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2025024882-A1 | FLUORINATED ADAMANTYL P2X7 RECEPTOR ANTAGONISTS AND USES THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2025-02-06 | — | — | WO | claimed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | claimed |
| EP-4127157-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2022072560-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2021194908-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2021-09-30 | — | — | WO | claimed |
| EP-0870757-B1 | Fluoro-substituted adamantane derivatives | PFIZER (US) | 2002-06-12 | — | — | EP | claimed |
| US-6057364-A | USED FOR TREATING NEUROLOGICAL DISORDERS, SUCH AS MEMORY LOSS AND PARKINSON'S DISEASE, AND BACTERIAL AND VIRAL INFECTIONS | PFIZER INC (US) | 2000-05-02 | — | — | US | claimed |
| EP-0870757-A2 | Fluoro-substituted adamantane derivatives | PFIZER INC. (US) | 1998-10-14 | — | — | EP | claimed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3340988-B1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI INC (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025024882-A1 | FLUORINATED ADAMANTYL P2X7 RECEPTOR ANTAGONISTS AND USES THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2025-02-06 | — | — | WO | disclosed |
| EP-4463443-A1 | INHIBITORS OF TRANSGLUTAMINASE | Aston University (GB) | 2024-11-20 | — | — | EP | disclosed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-0870757-B1 | Fluoro-substituted adamantane derivatives | PFIZER (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6057364-A | USED FOR TREATING NEUROLOGICAL DISORDERS, SUCH AS MEMORY LOSS AND PARKINSON'S DISEASE, AND BACTERIAL AND VIRAL INFECTIONS | PFIZER INC (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0870757-A2 | Fluoro-substituted adamantane derivatives | PFIZER INC. (US) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | GRM1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.